(EHC) Encompass Health - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US29261A1007

EHC: Rehabilitation, Hospitals, Healthcare, Therapy, Nursing, Medical

Encompass Health Corporation stands as a pivotal player in the post-acute care sector, specializing in rehabilitation services that bridge the gap between acute care and recovery. Their focus on inpatient rehabilitation hospitals underscores their commitment to addressing the complex needs of patients recovering from severe injuries or debilitating conditions such as strokes and hip fractures. This strategic positioning within the healthcare continuum highlights their role in optimizing patient outcomes and reducing healthcare costs through specialized care.

The companys operational model is rooted in a network of inpatient rehabilitation hospitals, where a multidisciplinary team of medical professionals, including physicians, nurses, and therapists, collaborates to provide comprehensive care. This integrated approach not only enhances patient recovery but also aligns with broader industry trends towards value-based care and cost-effective treatment solutions. Encompass Healths scale and operational efficiency are notable, allowing them to maintain a strong presence across the U.S. and Puerto Rico.

From a financial perspective, Encompass Health presents an intriguing profile for investors. With a market capitalization exceeding $10 billion, the company demonstrates substantial scale. The trailing P/E ratio of 22.31 and forward P/E of 20.58 suggest a valuation that reflects both current performance and future growth expectations. The price-to-book ratio of 4.88 indicates a premium on book value, potentially signaling confidence in the companys intangible assets and growth prospects. The price-to-sales ratio of 1.89 further highlights reasonable valuation relative to revenue.

Originally known as HealthSouth Corporation, the company rebranded as Encompass Health in 2018, a move that may signal a strategic shift towards a more holistic approach to healthcare. This rebranding could reflect an expansion of services or a change in corporate strategy, aligning with evolving industry dynamics. Incorporated in 1984 and headquartered in Birmingham, Alabama, Encompass Health

Additional Sources for EHC Stock

EHC Stock Overview

Market Cap in USD 10,149m
Sector Healthcare
Industry Medical Care Facilities
GiC Sub-Industry Health Care Facilities
IPO / Inception 1986-09-30

EHC Stock Ratings

Growth 5y 64.7%
Fundamental 44.7%
Dividend 4.50%
Rel. Strength 23.6
Analysts 4.85/5
Fair Price Momentum 98.34 USD
Fair Price DCF 82.67 USD

EHC Dividends

Dividend Yield 12m 0.52%
Yield on Cost 5y 0.92%
Annual Growth 5y -12.01%
Payout Consistency 93.1%

EHC Growth Ratios

Growth Correlation 3m 54.5%
Growth Correlation 12m 85.3%
Growth Correlation 5y 72.7%
CAGR 5y 12.62%
CAGR/Max DD 5y 0.33
Sharpe Ratio 12m 0.61
Alpha 18.85
Beta 0.826
Volatility 22.50%
Current Volume 1302.6k
Average Volume 20d 591.6k
What is the price of EHC stocks?
As of April 08, 2025, the stock is trading at USD 96.71 with a total of 1,302,566 shares traded.
Over the past week, the price has changed by -4.35%, over one month by -2.40%, over three months by +5.79% and over the past year by +18.32%.
Is Encompass Health a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, Encompass Health (NYSE:EHC) is currently (April 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 44.68 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EHC as of April 2025 is 98.34. This means that EHC is currently overvalued and has a potential downside of 1.69%.
Is EHC a buy, sell or hold?
Encompass Health has received a consensus analysts rating of 4.85. Therefor, it is recommend to buy EHC.
  • Strong Buy: 11
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for EHC stock price target?
According to ValueRays Forecast Model, EHC Encompass Health will be worth about 107.5 in April 2026. The stock is currently trading at 96.71. This means that the stock has a potential upside of +11.14%.
Issuer Forecast Upside
Wallstreet Target Price 117.3 21.2%
Analysts Target Price 116.5 20.5%
ValueRay Target Price 107.5 11.1%